Article Details
Retrieved on: 2021-07-01 11:37:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Corbus expanded its pipeline by licensing CRB-602 and CRB-601, the two innovative mAbs (monoclonal antibodies). The mAbs will target integrins to ...
Article found on: biopharmajournal.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here